Search

Your search keyword '"Mongkolsapaya, Juthathip"' showing total 514 results

Search Constraints

Start Over You searched for: Author "Mongkolsapaya, Juthathip" Remove constraint Author: "Mongkolsapaya, Juthathip"
514 results on '"Mongkolsapaya, Juthathip"'

Search Results

1. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

4. Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam

6. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity

7. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

8. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

9. Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination

10. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

11. Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

12. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

13. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination

15. Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.

16. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

17. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

18. An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

22. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays

23. Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies

24. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

25. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey

26. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

27. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

28. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

29. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

31. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.

32. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

33. Immunogenicity and durability against micron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

34. Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques

38. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera

39. Cooperativity and induced oligomerisation control the interaction of SARS- CoV-2 with its cellular receptor and patient-derived antibodies

40. Analysis of emergent bivalent antibody binding identifies the molecular reach as a critical determinant of SARS-CoV-2 neutralisation potency

41. Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody

48. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy

49. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

50. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2 directed antibody responses

Catalog

Books, media, physical & digital resources